查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012663

过敏诊断市场：依检测类型、技术、过敏原类型和最终用户划分－2026年至2032年全球市场预测

Allergy Diagnostics Market by Test Type, Technology, Allergen Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，过敏诊断市值将达到 63 亿美元，到 2026 年将成长至 66.7 亿美元，到 2032 年将达到 98.6 亿美元，复合年增长率为 6.61%。

主要市场统计数据
基准年 2025 63亿美元
预计年份：2026年 66.7亿美元
预测年份 2032 98.6亿美元
复合年增长率 (%) 6.61%

简要概述塑造现代过敏诊断策略的不断变化的临床需求和技术进步。

过敏诊断正处于临床需求与技术创新交汇点，其驱动力包括过敏性疾病盛行率的上升、临床医生诊断意识的增强以及患者对标靶治疗策略的需求。临床医生越来越依赖精准的诊断路径来区分致敏和具有临床意义的过敏反应，这使得高重复性和高品质的检测在门诊和住院环境中都显得尤为重要。同时，检测技术和检查室自动化的进步正在拓宽可行的检测选择范围，从而实现更精确的解读并支持精准医疗的发展。

该系统整合了临床、技术和营运趋势，从根本上重组了诊断流程，实现了个人化过敏护理。

在技​​术成熟、临床范式转移和医疗服务模式演进的推动下，过敏诊断领域正经历着一场变革。分子和成分分辨率诊断正从小众应用走向更广泛的临床应用，使临床医生能够分析复杂的致敏谱，并更准确地预测严重过敏反应的风险。同时，检测灵敏度和特异性的提高，以及多重检测平台的日益普及，正在减少诊断的不确定性，并缩短治疗决策的製定过程。

评估 2025 年关税环境将如何重塑整个诊断价值链的供应链、采购行为和区域製造策略。

政策和贸易措施可能对整个诊断供应链产生显着的连锁反应，2025年宣布的关税调整的累积影响将体现在製造、分销和检查室运营等各个环节。对进口试剂、仪器零件和耗材征收关税将推高依赖国际供应商的製造商的边际生产成本，这可能导致标价上涨和合约条款下行压力。对于检查室和终端用户而言，这意味着供应链韧性、库存计划以及与供应商签订长期合约的重要性日益凸显。

深入了解将检测方式、检测技术、过敏原类别和最终用户操作重点与商业性机会连结的目标细分。

细分市场洞察对于优化产品开发、商业化和部署策略至关重要。根据检测类型，诊断途径涵盖了从皮内试验和斑贴试验等皮肤检测方法到血清检测方法（包括血清特异性IgE检测和皮肤点刺试验）等多种选择。在血清分析中，化学化学冷光免疫检测和酵素免疫分析法与传统的放射性过敏原吸附试验并存，每种方法在处理能力、灵敏度和检查室相容性方面各有优劣。根据技术，市场还可以根据检测方法的选择进一步细分。化学冷光平台往往优先考虑自动化和灵敏度；酵素免疫分析法(ELISA) 为中型检查室提供了柔软性和成本效益；萤光酵素免疫分析法在某些配置下具有多重检测的优势；而放射性过敏原吸附试验在维持既定工作流程的情况下仍然适用。

临床实务、监管环境和基础设施投资的区域差异如何导致全球市场出现不同的采用路径。

区域趋势对临床实务和商业策略都有影响，因此在产品设计、监管合作和通路管理方面需要采取细緻入微的方法。在美洲，先进的血清检测方法已广泛应用于临床，而检查室网路集中化管理，并受到保险公司的严格监管。这就要求产品必须具备经证实的临床效用，并且拥有高效率的报销途径。在欧洲、中东和非洲，不同的法规结构和检查室能力意味着灵活的产品特性、本地伙伴关係关係以及对分散式检查的支援可以加速产品的普及，而区域临床指南则会影响过敏原检测组合和检测形式的优先顺序。在亚太地区，医疗基础设施的快速投资、都市区过敏性疾病盛行率的上升以及多样化的监管途径，为高通量集中式检查室和适应当地临床工作流程的照护现场（PoC）解决方案创造了机会。

决定哪家诊断服务提供者将在检查室实施和整合到临床指南方面占据主导的关键竞争行动和策略重点。

过敏诊断领域的竞争格局由多元化的大型诊断公司、专业的过敏检测套组製造商以及专注于创新和区域分销的灵活利基企业组成。成熟的製造商正投资于自动化、多重检测和数位化结果解读，以实现产品组合的差异化，并满足检查室对效率和整合报告功能的需求。专业公司则着重宣传其独特的诊断化学技术和支持成分分解诊断的临床证据，以促进过敏科医生和三级医疗机构的采用。此外，契约製造和试剂供应商在维持供应连续性方面发挥着至关重要的作用，而且其重要性日益凸显，尤其是在检查室寻求能够支持其在不断变化的监管要求下进行验证和品质保证的合作伙伴之际。

经营团队应优先采取策略性倡议，加强过敏诊断领域的证据、互通性、供应弹性和市场准入的准确性。

产业领导者应优先考虑一系列切实可行的倡议，将市场动态转化为可持续的竞争优势。首先，投资产生强有力的临床证据，不仅要证明分析效能，还要证明其临床效用，从而指导治疗决策并减少后续医疗资源的使用。其次，追求平台互通性，并与实验室资讯系统和电子健康记录深度集成，以简化临床医生的工作流程，并透过决策支援创造价值。第三，探索双重采购和区域生产安排，以实现供应链多元化，降低关税风险，并确保关键试剂和仪器组件的持续供应。

采用透明的混合方法研究途径，结合相关人员访谈、监管审查和技术检验，为策略建议提供支援。

本分析整合了严谨的混合方法检查室，以及对同行评审文献、监管指南和检测套组製造商技术文件的系统性二次文献回顾。主要研究着重于相关人员群体间的三角检验，检验了临床工作流程、检测偏好和推广障碍。二次文献则提供了有关技术性能特征、报销环境和过往监管先例的背景信息，指南对相关人员反馈的解读和情景构建。

重点关注技术进步、临床期望和供应限制之间的交集，并整合实用见解以支援策略决策。

过敏诊断正处于转折点，随着检测技术的进步、临床需求的演变以及供应链现实的交汇，过敏性疾病的识别和管理方式正在改变。检测准确性的提高使得患者分层和标靶治疗路径的发展更加有效，而营运创新则扩大了检测能力并缩短了反应时间。然而，贸易政策的变化以及监管和报销框架的区域差异等外部压力，要求我们制定前瞻性的策略，以增强供应链韧性、促进实证医学的产生并实现本地化的商业化。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 过敏诊断市场：检测类型

  • 皮内试验
  • 斑贴试验
  • 血清特异性IgE检测
    • 化学冷光免疫检测
    • 酵素免疫分析法
    • 放射性过敏原检测
  • 皮肤点刺试验

第九章：过敏诊断市场：依技术划分

  • 化学冷光免疫检测
  • 酵素免疫分析法
  • 萤光酵素免疫分析法
  • 放射性过敏原分选方法

第十章：依过敏原类型分類的过敏诊断市场

  • 接触性过敏原
  • 药物过敏原
  • 食物过敏原
  • 吸入性过敏原

第十一章 过敏诊断市场：依最终用户划分

  • 门诊部
  • 诊断检查室
  • 医院和诊所

第十二章 过敏诊断市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 过敏诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 过敏诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国过敏诊断市场

第十六章：中国过敏诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abnova Corporation
  • ACON Laboratories, Inc.
  • AESKU.GROUP GmbH
  • bioMerieux SA
  • Canon Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • EUROIMMUN Medizinische Labordiagnostika AG
  • HAL Allergy Group BV
  • Hitachi Chemical Diagnostics, Inc.
  • HOB Biotech Group Corp., Ltd.
  • Hollister Stier Allergy Inc.
  • Hycor Biomedical（GmbH）
  • HYCOR Biomedical Inc.
  • Laboratory Corporation of America Holdings
  • Lincoln Diagnostics, Inc.
  • Macro Array Diagnostics GmbH
  • Minaris Medical America, Inc.
  • Neogen Corporation
  • Omega Diagnostics Group PLC
  • Quest Diagnostics Incorporated
  • R-Biopharm AG
  • Siemens Healthineers AG
  • Stallergenes Greer International AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436901065A32

The Allergy Diagnostics Market was valued at USD 6.30 billion in 2025 and is projected to grow to USD 6.67 billion in 2026, with a CAGR of 6.61%, reaching USD 9.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.30 billion
Estimated Year [2026] USD 6.67 billion
Forecast Year [2032] USD 9.86 billion
CAGR (%) 6.61%

A concise orientation to the evolving clinical imperatives and technological advances shaping modern allergy diagnostic strategies

Allergy diagnostics sits at the nexus of clinical need and technological innovation, driven by rising prevalence of allergic conditions, greater diagnostic awareness among clinicians, and patient demand for targeted management strategies. Clinicians increasingly rely on precise diagnostic pathways to distinguish sensitization from clinically relevant allergy, and this has elevated the importance of reproducible, high-quality testing across outpatient and hospital settings. Concurrently, advances in assay technologies and laboratory automation have expanded the range of viable options, enabling more nuanced interpretations and supporting precision therapeutics.

Healthcare systems are also responding to pressures to reduce avoidable emergency visits and improve chronic disease management, which positions accurate and rapid allergy diagnostics as a cost-effective clinical tool in broader care pathways. Payers and procurement teams are seeking evidence of clinical utility, operational efficiency, and interoperability with electronic health records, prompting vendors and laboratories to prioritize validation, standardization, and reporting clarity. Taken together, these dynamics frame the immediate priorities for stakeholders seeking to invest in or adopt allergy diagnostic solutions.

How converging clinical, technological, and operational trends are fundamentally reshaping diagnostic pathways and enabling personalized allergy care

The landscape of allergy diagnostics is undergoing transformative shifts prompted by technological maturation, changing clinical paradigms, and evolving healthcare delivery models. Molecular and component-resolved diagnostics have moved from niche applications toward broader clinical acceptance, enabling clinicians to parse complex sensitization profiles and better predict risk for severe reactions. At the same time, improvements in assay sensitivity and specificity, alongside growing availability of multiplex platforms, are reducing diagnostic ambiguity and shortening the route to therapeutic decisions.

Operationally, diagnostic laboratories are adopting higher degrees of automation and digital integration, which improves throughput and reduces turnaround time while supporting consistent quality control. The rise of point-of-care initiatives and decentralized testing pathways reflects a broader trend toward shifting appropriate care closer to patients. Additionally, the integration of diagnostic outputs with clinical decision support tools is gaining traction, providing clinicians with evidence-based recommendations informed by test results, comorbidity profiles, and exposure histories. These convergent shifts are recasting the role of allergy diagnostics from confirmatory testing to a proactive enabler of personalized care.

Assessing how the 2025 tariff landscape will reshape supply chains, procurement behaviors, and regional manufacturing strategies across the diagnostics value chain

Policy actions and trade measures can have substantial ripple effects across the diagnostics supply chain, and the cumulative impact of tariff adjustments announced for 2025 will be observed across manufacturing, distribution, and laboratory operations. Tariffs on imported reagents, instrument components, and consumables raise the marginal cost of production for manufacturers that rely on international suppliers, which can translate into higher list prices and contracting pressures. For laboratories and end users, this increases the importance of supply chain resilience, inventory planning, and the negotiation of long-term supplier agreements.

Moreover, tariffs can incentivize regionalization of production and procurement, prompting multinational manufacturers to reassess sourcing footprints and consider nearshoring or dual-sourcing strategies to mitigate exposure. In parallel, procurement teams within hospitals, ambulatory centers, and diagnostics networks may shift purchasing priorities toward suppliers with domestic manufacturing capabilities or established tariff-mitigation measures. Over time, these adjustments may accelerate consolidation among suppliers who can absorb cost variability and maintain service levels, while smaller vendors and reagent suppliers face increased pressure to optimize operations or form strategic alliances to preserve market access.

Targeted segmentation insights linking test modalities, assay technologies, allergen categories, and end-user operational priorities to commercial opportunities

Segment insights are essential for tailoring product development, commercialization, and adoption strategies. Based on test type, diagnostic pathways range from skin-based modalities such as intradermal and patch testing to serum-based approaches including serum-specific IgE assays and skin prick testing; within serum analyses, chemiluminescence immunoassay and enzyme-linked immunosorbent assay methods coexist with legacy radioallergosorbent techniques, each offering distinct trade-offs in throughput, sensitivity, and laboratory compatibility. Based on technology, assay selection further differentiates the market because chemiluminescence platforms tend to favor automation and sensitivity, enzyme-linked immunosorbent assays deliver flexibility and cost efficiency for mid-volume labs, fluorescent enzyme immunoassays offer multiplexing advantages in some configurations, and radioallergosorbent methods remain relevant where established workflows persist.

Based on allergen type, diagnostic requirements vary substantially: contact allergens and drug allergens often require tailored exposure histories and specialized panels, food allergens demand high specificity to minimize unnecessary avoidance, and inhalant allergens benefit from well-validated component testing to guide immunotherapy. Based on end user, operational imperatives differ between ambulatory care centers prioritizing rapid, clinic-friendly workflows; diagnostic laboratories focusing on throughput, reproducibility, and result interpretation; and hospitals and clinics that integrate diagnostics into acute and chronic care pathways and require robust reporting for complex patients. These segmentation lenses highlight where clinical demand, laboratory capability, and commercial models intersect and where targeted investment can drive adoption.

How divergent regional clinical practices, regulatory landscapes, and infrastructure investments create distinct adoption pathways across global markets

Regional dynamics influence both clinical practice and commercial strategies, requiring nuanced approaches to product design, regulatory engagement, and channel management. In the Americas, robust clinical adoption of advanced serum-based assays is paired with concentrated laboratory networks and strong payer scrutiny, which together demand demonstrable clinical utility and efficient reimbursement pathways. In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and variable laboratory capacity mean that flexible product configurations, local partnerships, and support for decentralized testing can accelerate uptake, while regional clinical guidelines influence which allergen panels and assay formats are prioritized. In Asia-Pacific, rapid healthcare infrastructure investment, a growing prevalence of allergic conditions in urban centers, and diverse regulatory pathways create opportunities for both high-throughput centralized laboratories and point-of-care solutions adapted to local clinical workflows.

Taken together, these regional distinctions inform commercialization strategies, regulatory planning, and supply chain design, underscoring the importance of tailored evidence generation, localized service models, and partnerships with regional laboratory networks to achieve sustainable market penetration.

Key competitive behaviors and strategic priorities that determine which diagnostic providers will lead in laboratory adoption and clinical guideline integration

Competitive dynamics in allergy diagnostics are shaped by a mix of large diversified diagnostics firms, specialized allergy assay manufacturers, and agile niche players that focus on innovation or regional distribution. Established manufacturers invest in automation, multiplexing, and digital result interpretation to differentiate their portfolios and to meet laboratory demands for efficiency and integrated reporting. Specialized companies emphasize proprietary assay chemistries or clinical evidence supporting component-resolved diagnostics in order to drive adoption among allergists and tertiary care centers. Additionally, contract manufacturers and reagent suppliers play a critical role in maintaining supply continuity, particularly as laboratories seek partners capable of supporting validation and quality assurance under evolving regulatory expectations.

Strategic behaviors to watch include investments in partnerships with clinical networks and pharmacy chains for broader access, alliances with laboratory information system vendors to enhance result interoperability, and targeted evidence generation programs to secure favorable placement in clinical guidelines. Consolidation activity can be expected where scale enables improved pricing, distribution reach, and the ability to invest in next-generation assay development. New entrants that couple strong clinical data with scalable manufacturing and regulatory acumen will be well positioned to disrupt legacy business models.

Prioritized strategic initiatives for executives to strengthen evidence, interoperability, supply resilience, and go-to-market precision in allergy diagnostics

Industry leaders should prioritize a set of actionable initiatives to translate market dynamics into durable competitive advantage. First, invest in robust clinical evidence generation that demonstrates not only analytical performance but also clinical utility in guiding management decisions and reducing downstream healthcare utilization. Second, pursue platform interoperability and strong integration with laboratory information systems and electronic health records to streamline clinician workflows and enable value capture through decision support. Third, diversify supply chains and consider dual-sourcing or regional manufacturing arrangements to mitigate tariff exposure and ensure continuity of supply for critical reagents and instrument components.

Furthermore, adopt customer segmentation strategies that align commercial resources with the operational realities of ambulatory centers, high-throughput diagnostic laboratories, and integrated hospital systems. Complement product investments with scalable service offerings such as training, proficiency programs, and outcome tracking that lower adoption barriers. Finally, explore partnerships with therapeutics providers and allergy clinics to create bundled care pathways that link diagnostics to targeted interventions, thereby enhancing value propositions for payers and providers.

A transparent mixed-methods research approach integrating stakeholder interviews, regulatory review, and technical validation to underpin strategic recommendations

This analysis synthesizes findings derived from a rigorous mixed-methods research approach combining primary qualitative interviews with laboratory directors, practicing allergists, procurement leads, and industry executives alongside systematic secondary review of peer-reviewed literature, regulatory guidances, and technical documentation from assay manufacturers. Primary research emphasized triangulation across stakeholder groups to validate clinical workflows, assay preferences, and adoption barriers. Secondary sources provided context on technology performance characteristics, reimbursement environments, and historic regulatory precedents, which informed interpretation of stakeholder input and scenario development.

Data validation included cross-checking assay attributes and claimed performance characteristics against device labeling and regulatory summaries, while methodological transparency was maintained through clear documentation of inclusion criteria, interview protocols, and synthesis techniques. Limitations include variability across regional regulatory regimes and the evolving nature of trade policies, which may affect supply chain dynamics; these factors were addressed through scenario analysis and sensitivity checks to ensure robustness of recommendations. The result is a pragmatic evidence base designed to support strategic planning without relying on speculative forecasts.

Synthesis of actionable insights highlighting where technological advances, clinical expectations, and supply constraints intersect to inform strategic decisions

Allergy diagnostics is positioned at an inflection point where improved assay technologies, evolving clinical expectations, and supply chain realities converge to redefine how allergic disease is identified and managed. Precision in testing is enabling more effective patient stratification and targeted therapeutic pathways, while operational innovations are expanding capacity and improving turnaround. However, external pressures including trade policy shifts and regional heterogeneity in regulatory and reimbursement frameworks require proactive strategies around supply chain resilience, evidence generation, and localized commercialization.

Looking ahead, stakeholders who align product design with demonstrable clinical value, ensure interoperability with clinical systems, and adopt flexible manufacturing and distribution models will be best placed to capture opportunity and sustain adoption. Strategic collaboration between diagnostic providers, clinical networks, and payers will be crucial to translate diagnostic advances into measurable improvements in care pathways and patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allergy Diagnostics Market, by Test Type

  • 8.1. Intradermal Test
  • 8.2. Patch Test
  • 8.3. Serum-Specific IgE Test
    • 8.3.1. Chemiluminescence Immunoassay
    • 8.3.2. Enzyme-Linked Immunosorbent Assay
    • 8.3.3. Radioallergosorbent Test
  • 8.4. Skin Prick Test

9. Allergy Diagnostics Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
  • 9.2. Enzyme-Linked Immunosorbent Assay
  • 9.3. Fluorescent Enzyme Immunoassay
  • 9.4. Radioallergosorbent Test

10. Allergy Diagnostics Market, by Allergen Type

  • 10.1. Contact Allergen
  • 10.2. Drug Allergen
  • 10.3. Food Allergen
  • 10.4. Inhalant Allergen

11. Allergy Diagnostics Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics

12. Allergy Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Allergy Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Allergy Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Allergy Diagnostics Market

16. China Allergy Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abnova Corporation
  • 17.6. ACON Laboratories, Inc.
  • 17.7. AESKU.GROUP GmbH
  • 17.8. bioMerieux SA
  • 17.9. Canon Inc.
  • 17.10. Danaher Corporation
  • 17.11. Eurofins Scientific SE
  • 17.12. EUROIMMUN Medizinische Labordiagnostika AG
  • 17.13. HAL Allergy Group B.V.
  • 17.14. Hitachi Chemical Diagnostics, Inc.
  • 17.15. HOB Biotech Group Corp., Ltd.
  • 17.16. Hollister Stier Allergy Inc.
  • 17.17. Hycor Biomedical (GmbH)
  • 17.18. HYCOR Biomedical Inc.
  • 17.19. Laboratory Corporation of America Holdings
  • 17.20. Lincoln Diagnostics, Inc.
  • 17.21. Macro Array Diagnostics GmbH
  • 17.22. Minaris Medical America, Inc.
  • 17.23. Neogen Corporation
  • 17.24. Omega Diagnostics Group PLC
  • 17.25. Quest Diagnostics Incorporated
  • 17.26. R-Biopharm AG
  • 17.27. Siemens Healthineers AG
  • 17.28. Stallergenes Greer International AG
  • 17.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLERGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ALLERGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)